ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 2266 - 2280 of 5996 products
Harbour BioMed Starts Australian Trial of CTLA-4 Checkpoint Inhibitor
$5.00
Available
Ascentage and Henlius to Test Two-drug Combination in China Leukemia Trial
$5.00
Available
Shanghai Green Valley Surprises with China Approval for Alzheimer's Treatment
$5.00
Available
QYuns Out-Licenses Ex-China Rights for Autoimmune Portfolio to Seneca
$5.00
Available
Denovo Closes $43 Million B Round for Biomarker Driven Drug Development
$5.00
Available
I-Mab Files for $100 Million IPO on the NASDAQ Exchange
$5.00
Available
QnQuality Pharma Raises $15 Million for Oncotherapy Side-Effect Drugs
$5.00
Available
QnQuality Pharma Raises $15 Million for Oncotherapy Side-Effect Drugs
$5.00
Available
Terns Granted US Fast Track Status for NASH Candidate
$500.00
Available
Ascentage Pharma Rises 10% in First Trading Session after IPO
$5.00
Available
Ansun Biopharma Reports China Approvals for Two Trials of Anti-Infective
$5.00
Available
China Aesthetics Company Completes $30 Million US IPO
$5.00
Available
YiXi Biotech Closes Angel Round for Microbial Treatments
$5.00
Available
Visen Pharma Approved for China Phase III Trial of Growth Hormone Drug
$5.00
Available
Ascentage Pharma Completes $53 Million Hong Kong IPO
$5.00
Available